Orbis Medicines has successfully raised €90 million (approximately $93 million) in a Series A funding round aimed at developing oral macrocycle drugs that target popular biologic therapies. The funding round, which marks the beginning of 2025's fundraising tracker, was led by NEA and included prominent investors such as Novo Holdings and Eli Lilly. The Danish biotech firm plans to utilize automated chemistry and machine learning to enhance its drug design capabilities. This financing is part of a growing trend in Denmark, which is emerging as a significant hub for biotech innovation.